Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 13/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6707777 | 0.89 | HIF1A (0.38) | KLKB1HIF1ALRRK2ROCK1 | |
| SCHEMBL6710204 | 0.89 | LMNA (0.43) | HIF1AKMT2AMEN1RAB9A | |
| SCHEMBL6708990 | 0.88 | HIF1A (0.51) | HIF1AROCK1 | |
| SCHEMBL6713809 | 0.87 | HIF1A (0.43) | HIF1AROCK1 | |
| SCHEMBL6708097 | 0.87 | HIF1A (0.43) | HIF1AROCK1 | |
| SCHEMBL6707931 | 0.87 | GPR27 (0.41) | HIF1AKMT2AMEN1BRD4 | |
| SCHEMBL6714271 | 0.87 | HIF1A (0.48) | HIF1AROCK1 | |
| SCHEMBL6709855 | 0.86 | F2 (0.43) | F2PLGPLAUKLKB1PRSS1 | |
| SCHEMBL6713561 | 0.86 | BRD4 (0.38) | HIF1ALRRK2ROCK1KMT2ABRD4 | |
| SCHEMBL6708048 | 0.85 | TNIK (0.36) | KLKB1HIF1ALRRK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | F2 3040/4885PLG 1591/4885PLAU 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.